biology

Lorenz Studer

Lorenz Studer is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Lorenz Studer rather than just read about it. In short: Lorenz Studer (born March 5, 1966) is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City.

Key takeaways

Lorenz Studer belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Lorenz Studer to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Lorenz Studer from memory before moving on to harder problems.

Reference excerpt

Lorenz Studer (born March 5, 1966) is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City. He is a developmental biologist and neuroscientist who is pioneering the generation of midbrain dopamine neurons for transplantation and clinical applications. His expertise in cell engineering spans a wide range of cells/tissues within the nervous system geared toward disease modeling and exploring cell replacement therapy. Currently, he is a member of the Developmental Biology Program and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center and a professor of Neuroscience at Weill Cornell Medical College in New York City, NY. In 2015, he was named a recipient of the MacArthur Fellowship (also known as the "Genius Grant") for his innovative work on stem cell and Parkinson's disease research. Implementation of Studer's cell replacement therapy clinical trial which utilizes dopamine neurons generated from human embryonic/pluripotent stem cells for Parkinson's disease would be the first of its kind. The clinical trial which already has begun recruiting patients, is expected to receive the FDA's study permission by the end of 2020, with an anticipated start date in 2021. Most recently, Studer was awarded an $8.95 million grant from the Aligning Science Across Parkinson's (ASAP) Initiative, in partnership with the Michael J. Fox Foundation. Memorial Sloan Kettering Cancer Center, where Studer works, was designated as the lead grant recipient among the five that will be sharing the overall award.

Research In 1998, while at the lab of Ronald D. McKay at the National Institutes of Health in Bethesda, Maryland, he developed techniques that facilitate the generation of dopamine cells, the primary cell type affected in Parkinson's disease in vitro from dividing precursor cells. He successfully demonstrated that upon transplantation, these newly developed dopaminergic neurons can improve clinical symptoms in Parkinsonian rat models. Over the years, he has developed a variety of novel cell engineering strategies for developing specific neural cell types in culture. Most notably, he has devised protocols for the transition (or "differentiation") of human pluripotent stem cells into neural and neural crest tissues and for the generation of functional dopaminergic neurons in large-scale quantities. In long-term studies, Studer demonstrated that these cells are non-tumorigenic, can integrate into the host brain and may serve as functional replacements for the substantia nigra dopamine neurons which die in Parkinson's disease. Current research efforts also include directing the fate and age of human pluripotent stem cells, and using pluripotent stem cells as valuable tools for modeling human diseases such as Familial Dysautonomia, Hirschsprung's disease, neurodevelopmental disorders such as autism, melanocyte-related diseases, as well as mechanisms of aging. On aging research, he has also been among the first to manipulate cellular age in pluripotent-derived lineages. Other major contributions include the directed differentiation of nuclear transfer embryonic stem cells and parthenogenetic stem cells into specific neuron types. His lab was also the first to demonstrate "therapeutic cloning" in a mouse model of a central nervous system disorder. Overall, Studer's decades long investigation into neurological diseases such as Parkinson's disease and clinical applications of stem cells has helped advance the field of cell replacement therapy. He currently also leads a multidisciplinary consortium to pursue the application of human stem cell-derived dopamine neurons for the treatment of Parkinson's disease.

Education and career Studer, a native of Switzerland, graduated from medical school in 1991 and earned his neuroscience doctoral degree in 1994 at the University of Bern. There, he worked with Christian Spenger, culminating in the first clinical trial of fetal tissue transplantation for Parkinson's disease in Switzerland in 1995. The following year, he joined Ronald McKay's lab at the National Institute of Health (NIH) to investigate how neural cells could be isolated, cultured, and differentiated to produce neurons with the aim of restoring brain function in Parkinson's disease mouse models. In 2000, Studer moved to New York City where he embarked on his own research program at Memorial-Sloan Kettering Cancer Center (MSKCC) with a focus on exploring stem cells and brain repair. He also established the Sloan-Kettering Center for Stem Cell Biology and has been involved in a number of stem cell research committees and initiatives including the Tri-Institutional Stem Cell Initiative, (a collaboration between Memorial-Sloan Kettering Cancer Center, Rockefeller University, and Weill-Cornell Medical College), Michael J. Fox Foundation for Parkinson's disease research, and the New York Stem Cell Foundation. In 2016, Studer became a scientific cofounder of BlueRock Therapeutics, a biotech company to develop induced pluripotent stem cell (iPSC) therapies for degenerative conditions like Parkinson's disease and heart failure. Its launch was the product of a joint venture between Versant Ventures and Bayer AG, with a $225 million investment – one of the largest-ever series A financings for a biotech company. In 2019, BlueRock was acquired by Bayer AG, in a transaction valued at up to $1 billion.

Awards and memberships Louise and Allston Boyer Young Investigator in Basic Research, MSKCC (2005) Annemarie Opprecht Award for Parkinson's Disease Research (2012) Member, American Society for Clinical Investigation (2014) MacArthur Fellows Program (2015) Ogawa-Yamanaka Stem Cell Prize, Gladstone Institute (2017) Gabbay Award (2018) Member of the National Academy of Medicine (2024)

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with Lorenz Studer

Start with the simplest possible case. Write down what Lorenz Studer claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Lorenz Studer before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Lorenz Studer ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Lorenz Studer

In research: Lorenz Studer appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Lorenz Studer in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Lorenz Studer is common in secondary-school and first-year university syllabi. It links to neighbouring topics 1966 births, Living people, MacArthur Fellows, so understanding it makes those chapters shorter.
In everyday life: Look for Lorenz Studer outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Lorenz Studer” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Lorenz Studer in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Lorenz Studer means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Lorenz Studer out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Lorenz Studer in simple terms?

Lorenz Studer (born March 5, 1966) is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City.

Why does Lorenz Studer matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Lorenz Studer?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Lorenz Studer.